Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Imugene ( (AU:IMU) ) has issued an announcement.
Imugene Limited has notified the market of the issue of 88,233 restricted stock units and 875,675 performance rights awards under its employee incentive scheme, effective 15 December 2025. The unquoted equity issuance, which will not be listed on the ASX, underscores the company’s continued use of equity-based compensation to attract and retain talent, aligning staff incentives with long-term shareholder value and supporting the execution of its strategic and clinical development objectives.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australian biotechnology company listed on the ASX that focuses on developing immuno-oncology therapies. The company typically advances cancer treatments through novel platforms and partners within the global biopharmaceutical and healthcare markets.
YTD Price Performance: -75.76%
Average Trading Volume: 1,859,614
Technical Sentiment Signal: Sell
Current Market Cap: A$96.19M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.